Bausch Health Companies Inc. Business Acquisition, Pro Forma Net Income (Loss)
Bausch Health Companies Inc. (BHC) reported Business Acquisition, Pro Forma Net Income (Loss) of -$619.00 million for the 12-month period ending 2015-12-31, per its 8-K filed 2018-08-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2018-08-10
- Bausch Health Companies Inc. business acquisition, pro forma net income (loss) for the quarter ending 2015-12-31 was -$375.30M.
- Bausch Health Companies Inc. business acquisition, pro forma net income (loss) for the quarter ending 2015-09-30 was $56.20M, a 298.58% increase year-over-year.
- Bausch Health Companies Inc. business acquisition, pro forma net income (loss) for the quarter ending 2015-06-30 was -$30.10M.
- Bausch Health Companies Inc. business acquisition, pro forma net income (loss) for the quarter ending 2015-03-31 was -$269.80M.
- Bausch Health Companies Inc. business acquisition, pro forma net income (loss) for fiscal 2014 was -$375.00M.
- Bausch Health Companies Inc. business acquisition, pro forma net income (loss) for fiscal 2013 was -$801.90M.
- Bausch Health Companies Inc. business acquisition, pro forma net income (loss) for fiscal 2012 was -$709.60M.
- Bausch Health Companies Inc. business acquisition, pro forma net income (loss) for fiscal 2011 was -$43.34M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 3 month as first filed | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month as first filed | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month as first filed | Business Acquisition, Pro Forma Net Income (Loss) 12 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2015-12-31 | -$375.30M derived: 8-K 12 month − 10-Q 9 month · filed 2018-08-10 | -$319.10M derived: sum of 2 quarters · filed 2018-08-10 | -$349.20M derived: sum of 3 quarters · filed 2018-08-10 | -$619.00M 8-K · filed 2018-08-10 | -$619.10M 10-K · filed 2016-04-29 | |||
| 2015-09-30 | $56.20M 10-Q · filed 2016-11-09 | $57.80M 10-Q · filed 2015-10-26 | $26.10M derived: sum of 2 quarters · filed 2016-11-09 | -$243.70M 10-Q · filed 2016-11-09 | -$258.20M 10-Q · filed 2015-10-26 | -$280.00M derived: sum of 4 quarters · filed 2017-03-01 | ||
| 2015-06-30 | -$30.10M 10-Q · filed 2016-08-09 | -$24.90M 10-Q · filed 2015-07-28 | -$299.90M 10-Q · filed 2016-08-09 | -$329.60M 10-Q · filed 2015-07-28 | -$336.20M derived: sum of 3 quarters · filed 2017-03-01 | -$322.10M derived: sum of 4 quarters · filed 2017-03-01 | ||
| 2015-03-31 | -$269.80M 10-Q · filed 2016-06-07 | $93.80M 10-Q · filed 2015-04-30 | -$306.10M derived: sum of 2 quarters · filed 2017-03-01 | -$292.00M derived: sum of 3 quarters · filed 2017-03-01 | -$343.70M derived: sum of 4 quarters · filed 2017-03-01 | |||
| 2014-12-31 | -$36.30M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$22.20M derived: sum of 2 quarters · filed 2017-03-01 | -$73.90M derived: sum of 3 quarters · filed 2017-03-01 | -$375.00M 10-K · filed 2017-03-01 | $909.30M 10-K · filed 2015-02-25 | |||
| 2014-09-30 | $14.10M 10-Q · filed 2015-10-26 | $279.80M 10-Q · filed 2014-10-24 | -$37.60M derived: sum of 2 quarters · filed 2015-10-26 | -$338.70M 10-Q · filed 2015-10-26 | $376.10M 10-Q · filed 2014-10-24 | $110.50M derived: sum of 4 quarters · filed 2016-04-29 | ||
| 2014-06-30 | -$51.70M 10-Q · filed 2015-07-28 | $127.70M 10-Q · filed 2014-08-01 | -$353.80M 10-Q · filed 2015-07-28 | $102.50M 10-Q · filed 2014-08-01 | $96.40M derived: sum of 3 quarters · filed 2016-04-29 | -$811.40M derived: sum of 4 quarters · filed 2016-04-29 | ||
| 2014-03-31 | -$73.90M 10-Q · filed 2015-04-30 | -$25.10M 10-Q · filed 2014-05-09 | $148.10M derived: sum of 2 quarters · filed 2016-04-29 | -$759.70M derived: sum of 3 quarters · filed 2016-04-29 | -$781.20M derived: sum of 4 quarters · filed 2016-04-29 | |||
| 2013-12-31 | $222.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-04-29 | -$685.80M derived: sum of 2 quarters · filed 2016-04-29 | -$707.30M derived: sum of 3 quarters · filed 2016-04-29 | -$801.90M 10-K · filed 2016-04-29 | -$821.15M 10-K · filed 2014-02-28 | |||
| 2013-09-30 | -$907.80M 10-Q · filed 2014-10-24 | -$960.33M 10-Q · filed 2013-11-01 | -$929.30M derived: sum of 2 quarters · filed 2014-10-24 | -$1.02B 10-Q · filed 2014-10-24 | -$1.05B 10-Q · filed 2013-11-01 | -$1.18B derived: sum of 4 quarters · filed 2015-02-25 | ||
| 2013-06-30 | -$21.50M 10-Q · filed 2014-08-01 | $27.17M 10-Q · filed 2013-08-07 | -$104.20M 10-Q · filed 2014-08-01 | $29.84M 10-Q · filed 2013-08-07 | -$271.27M derived: sum of 3 quarters · filed 2015-02-25 | -$384.34M derived: sum of 4 quarters · filed 2015-02-25 | ||
| 2013-03-31 | -$83.30M 10-Q · filed 2014-05-09 | $5.02M 10-Q · filed 2013-05-03 | -$249.77M derived: sum of 2 quarters · filed 2015-02-25 | -$362.84M derived: sum of 3 quarters · filed 2015-02-25 | -$392.68M derived: sum of 4 quarters · filed 2015-02-25 | |||
| 2012-12-31 | -$166.47M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-25 | -$279.54M derived: sum of 2 quarters · filed 2015-02-25 | -$309.38M derived: sum of 3 quarters · filed 2015-02-25 | -$709.60M 10-K · filed 2015-02-25 | -$97.55M 10-K · filed 2013-02-28 | |||
| 2012-09-30 | -$113.07M 10-Q · filed 2013-11-01 | $13.16M 10-Q · filed 2012-11-05 | -$142.91M derived: sum of 2 quarters · filed 2013-11-01 | -$543.13M 10-Q · filed 2013-11-01 | $9.78M 10-Q · filed 2012-11-05 | -$297.75M derived: sum of 4 quarters · filed 2013-11-01 | ||
| 2012-06-30 | -$29.84M 10-Q · filed 2013-08-07 | -$5.41M 10-Q · filed 2012-08-03 | -$80.39M 10-Q · filed 2013-08-07 | -$9.41M 10-Q · filed 2012-08-03 | -$184.68M derived: sum of 3 quarters · filed 2013-08-07 | -$166.39M derived: sum of 4 quarters · filed 2013-08-07 | ||
| 2012-03-31 | -$40.66M 10-Q · filed 2013-05-03 | -$64.00K 10-Q · filed 2012-05-04 | -$154.84M derived: sum of 2 quarters · filed 2013-05-03 | -$136.55M derived: sum of 3 quarters · filed 2013-05-03 | -$85.08M derived: sum of 4 quarters · filed 2013-05-03 | |||
| 2011-12-31 | -$114.18M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28 | -$95.89M derived: sum of 2 quarters · filed 2013-02-28 | -$44.41M derived: sum of 3 quarters · filed 2013-02-28 | -$43.34M 10-K · filed 2013-02-28 | $154.90M 10-K · filed 2012-02-29 | |||
| 2011-09-30 | $18.29M 10-Q · filed 2012-11-05 | $32.72M 10-Q · filed 2011-11-04 | $69.77M derived: sum of 2 quarters · filed 2012-11-05 | $70.84M 10-Q · filed 2012-11-05 | $122.28M 10-Q · filed 2011-11-04 | -$74.28M derived: sum of 4 quarters · filed 2012-11-05 | ||
| 2011-06-30 | $51.48M 10-Q · filed 2012-08-03 | $71.41M 10-Q · filed 2011-08-08 | $49.62M 10-Q · filed 2012-08-03 | $98.76M 10-Q · filed 2011-08-08 | -$92.58M derived: sum of 3 quarters · filed 2012-08-03 | -$194.73M derived: sum of 4 quarters · filed 2012-08-03 | ||
| 2011-03-31 | $14.04M 10-Q · filed 2012-05-04 | -$144.05M derived: sum of 2 quarters · filed 2012-05-04 | -$246.20M derived: sum of 3 quarters · filed 2012-05-04 | -$252.66M derived: sum of 4 quarters · filed 2012-05-04 | ||||
| 2010-12-31 | -$158.09M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | -$260.24M derived: sum of 2 quarters · filed 2012-02-29 | -$266.71M derived: sum of 3 quarters · filed 2012-02-29 | -$323.97M 10-K · filed 2012-02-29 | ||||
| 2010-09-30 | -$102.15M 10-Q · filed 2011-11-04 | -$108.61M derived: sum of 2 quarters · filed 2011-11-04 | -$165.88M 10-Q · filed 2011-11-04 | |||||
| 2010-06-30 | -$6.46M 10-Q · filed 2011-08-08 | -$49.49M 10-Q · filed 2011-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |